RaySearch Receives Order for RayStation and RayCare in Italy

RaySearch Laboratories AB (publ) announces that Ion Beam Applications S.A. (IBA), market leader in proton therapy, has placed an order for RayStation®* treatment planning system and the oncology information system RayCare®* for installation at CRO National Cancer Institute (C.R.O.) in Aviano, Italy. RaySearch partnered with IBA for the public tender, with IBA serving as the main system integrator.

The order includes implementation of both RayStation and RayCare at C.R.O. Aviano. The combination of RayStation and RayCare provides an integrated and unified solution throughout the complete workflow, when combined with an IBA proton therapy machine. 

IBA signed the contract with C.R.O. Aviano in November 2021 following a comprehensive vendor selection process. RaySearch partnered with IBA for the public tender and the center has now decided to select RayStation and RayCare. RayStation includes a complete set of licencs for pencil beam scanning, including automatic proton therapy planning using machine learning techniques. RayCare includes licences to cover the workflow management and the treatment delivery for all patients treated with proton therapy.

C.R.O. Aviano is expected to start treating patients by the end of 2024.

Johan Löf, founder and CEO, RaySearch, says: “We are very pleased to provide C.R.O. Aviano with RayStation and RayCare. The adoption of both RaySearch solutions at C.R.O. Aviano will enhance implementation efficiency as well as the possibility to optimize clinical excellence of proton therapy at this center. For RaySearch, this agreement further strengthens our prominent role in both treatment planning and oncology information systems for proton therapy centers in Europe.”

The total order value is EUR 1.7 million (approximately SEK 19 million). A service contract is not included but is expected to be added at a later stage.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version